The University of Liège wishes to use cookies or trackers to store and access your personal data, to perform audience measurement. Some cookies are necessary for the website to function. Cookie policy.
![]() ![]() | Kirkove, D.* , STREEL, S.* , ORY, A., AUBOUY, G., DE JODE, E., JERUSALEM, G., GAGNAYRE, R., & Pétré, B. (May 2022). Immuno’Act - J’agis sur les effets secondaires liés à mon immunothérapie oncologique [Poster presentation]. Congrès Éducation Thérapeutique du Patient 2022, Montpellier, France. ![]() * These authors have contributed equally to this work. |
![]() ![]() | Poiré, X., Graux, C., ORY, A., Herman, J., Baron, F., Schoemans, H., Lewalle, P., De Becker, A., Deeren, D., Berneman, Z., Kerre, T., Zachée, P., Selleslag, D., & Beguin, Y. (2022). Sequential administration of 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective study from the Belgian Hematology Society (BHS). Bone Marrow Transplantation, 57, 116-118. doi:10.1038/s41409-021-01464-x ![]() |
![]() ![]() | Servais, S., Baron, F., LECHANTEUR, C., SEIDEL, L., Selleslag, D., Maertens, J., BAUDOUX, E., Zachee, P., Van Gelder, M., Noens, L., Kerre, T., Lewalle, P., Schroyens, W., ORY, A., & Beguin, Y. (2018). Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graftversus- host disease: A multicenter prospective study. Oncotarget, 9 (29), 20590-20604. doi:10.18632/oncotarget.25020 ![]() |
![]() ![]() | HANNON, M., BEGUIN, Y., Ehx, G., SERVAIS, S., SEIDEL, L., Graux, C., Maertens, J., Kerre, T., Daulne, C., de Bock, M., Fillet, M., ORY, A., WILLEMS, E., GOTHOT, A., Humblet-Baron, S., & BARON, F. (15 July 2015). Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation following Flu-TBI versus TLI-ATG Conditioning. Clinical Cancer Research, 21 (14), 3131-9. doi:10.1158/1078-0432.CCR-14-3374 ![]() |
![]() ![]() | Baron, F., Zachée, P., Maertens, J., Kerre, T., ORY, A., SEIDEL, L., Graux, C., Lewalle, P., Van Gelder, M., Theunissen, K., WILLEMS, E., Emonts, M.-P., De Becker, A., & Beguin, Y. (2015). Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society. Journal of Hematology and Oncology, 8, 4. doi:10.1186/s13045-014-0098-9 ![]() |
![]() ![]() | BEGUIN, Y., ZACHEE, P., MAERTENS, J., KERRE, T., ORY, A., SEIDEL, L., GRAUX, C., LEWALLE, P., VAN GELDER, M., THEUNISSEN, K., WILLEMS, E., EMONDS, M.-P., DE BECKER, A., & BARON, F. (December 2014). Nonmyeloablative allogeneic hematopoietic cell transplantation following Fludarabine Plus 2 Gy TBI or ATG Plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society. Blood, 124 (21), 542. ![]() |